RPG Life Sciences has announced that its subsidiary, RPG Active Pharma, will acquire the active pharmaceutical ingredients (API) and intermediates business of Raghava Life Sciences for ₹135 crore. This transaction, structured as a slump sale, aims to enhance RPG Active Pharma’s capabilities in research, development, and manufacturing, helping to establish a more diversified API organization. Raghava Life Sciences operates a WHO-GMP and EU-GMP certified manufacturing facility in Hyderabad, contributing a robust portfolio of 22 commercialized APIs across therapeutic areas such as diabetes and cardiovascular diseases. This acquisition follows RPG Active Pharma’s recent purchase of Actis Generics and is expected to strengthen its market presence and operational scale in the growing API sector.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.business-standard.com/markets/capital-market-news/rpg-life-sciences-rises-on-deal-to-acquire-api-business-of-raghava-life-sciences-126090300220_1.html
